Lindström, UlfDi Giuseppe, DanielaDelcoigne, BénédicteGlintborg, BenteMöller, BurkhardCiurea, AdrianPombo-Suarez, ManuelSanchez-Piedra, CarlosEklund, KariRelas, HeikkiGudbjornsson, BjornLove, Thorvardur JonJones, Gareth T.Codreanu, CatalinIonescu, RuxandraNekvindova, LucieZávada, JakubAtas, NuhYolbas, ServetFagerli, Karen MindeMichelsen, BrigitteRotarTomšič, MatijaIannone, FlorenzoSantos, Maria JoseAvila-Ribeiro, PedroØrnbjerg, Lykke MidtbøllØstergaard, MikkelJacobsson, Lennart T.H.Askling, JohanNissen, Michael J.2021-11-022021-11-022021-11Lindström, U, Di Giuseppe, D, Delcoigne, B, Glintborg, B, Möller, B, Ciurea, A, Pombo-Suarez, M, Sanchez-Piedra, C, Eklund, K, Relas, H, Gudbjornsson, B, Love, T J, Jones, G T, Codreanu, C, Ionescu, R, Nekvindova, L, Závada, J, Atas, N, Yolbas, S, Fagerli, K M, Michelsen, B, Rotar, Tomšič, M, Iannone, F, Santos, M J, Avila-Ribeiro, P, Ørnbjerg, L M, Østergaard, M, Jacobsson, L T H, Askling, J & Nissen, M J 2021, 'Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration', Annals of the Rheumatic Diseases, vol. 80, no. 11, 220097, pp. 1410-1418. https://doi.org/10.1136/annrheumdis-2021-2200970003-4967ORCID: /0000-0003-0016-7591/work/99292748Jisc: 48001c17edca4d99b98be99856efd709https://hdl.handle.net/2164/17428Funding This work was supported by Novartis. Novartis had no influence on the data collection, statistical analyses, manuscript preparation or decision to submit. The work was also supported by NordForsk92478106engarthritismethotrexatepsoriatictumour necrosis factor inhibitorsR MedicineRheumatologyImmunology and AllergyImmunologyGeneral Biochemistry,Genetics and Molecular BiologySupplementary InformationSupplementary DataRJournal article10.1136/annrheumdis-2021-220097http://www.scopus.com/inward/record.url?scp=85107521561&partnerID=8YFLogxK8011